Compass Pathways Plc Cash Flow Conversion Efficiency
Compass Pathways Plc cash flow conversion efficiency. Based on the latest financial reports, Compass Pathways Plc (CMPS) has a cash flow conversion efficiency ratio of 0.715x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.79 Million) by net assets ($-52.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Compass Pathways Plc (2018–2025)
Cash flow conversion efficiency of Compass Pathways Plc from 2018 to 2025. This chart illustrates how Compass Pathways Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CMPS stock price and chart for real-time trading data and today's change.
Compass Pathways Plc Cash Flow Conversion Ratio Explained
Compass Pathways Plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Compass Pathways Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Compass Pathways Plc ranked by their cash flow conversion efficiency. Also see Compass Pathways Plc (CMPS) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Yisheng Livestock & Poultry Breeding Co Ltd
SHE:002458
|
0.021x |
|
U-Haul Holding Company
NYSE:UHAL
|
0.031x |
|
Bank Leumi Le-Israel B.M
TA:LUMI
|
0.131x |
|
OVH GROUPE UNSP.ADR/1/2
F:7U70
|
N/A |
|
Yunnan Salt & Salt Chemical Industry Co Ltd
SHE:002053
|
0.031x |
|
JM Financial Limited
NSE:JMFINANCIL
|
-0.028x |
|
NINGBO HENGSHUAI Co. LTD.
SHE:300969
|
0.042x |
|
Netcare
JSE:NTC
|
0.220x |
Annual Cash Flow Conversion Efficiency for Compass Pathways Plc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Compass Pathways Plc from 2018 to 2025. Review financial flexibility index of Compass Pathways Plc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-52.85 Million | $-157.24 Million | 2.975x | +486.18% |
| 2024-12-31 | $154.69 Million | $-119.19 Million | -0.770x | -78.61% |
| 2023-12-31 | $225.74 Million | $-97.38 Million | -0.431x | +25.85% |
| 2022-12-31 | $181.28 Million | $-105.45 Million | -0.582x | -144.21% |
| 2021-12-31 | $284.41 Million | $-67.75 Million | -0.238x | -13.15% |
| 2020-12-31 | $196.56 Million | $-41.38 Million | -0.211x | +89.93% |
| 2019-12-31 | $8.52 Million | $-17.81 Million | -2.091x | -406.57% |
| 2018-12-31 | $-14.37 Million | $-9.80 Million | 0.682x | -- |
About Compass Pathways Plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly … Read more